Eli Lilly Says EloraTZP Cut Weight Up To 23.3% Vs. 14.8% For Tirzepatide In Phase 2b Diabetes Trial; Plans Phase 3 In Q4
Share
Why It Matters
Eli Lilly tested a new weight loss medicine that worked better than tirzepatide. The company saw strong early results and plans bigger human tests soon.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.